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9What is already known about this topic? Inhaled corticosteroids are the mainstay of asthma treatment, but response to
medication is variable.
What does this article add to our knowledge? Lung function decline over 2 decades was slower for adults with atopic
asthma under sustained inhaled corticosteroid treatment compared with their nonatopic peers.
How does this study impact current management guidelines? Biomarkers of allergic inﬂammation could be useful to
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FVC- Forced vital capacity
HDM-House-dust mite
ICS- Inhaled corticosteroid
IQR- Interquartile rangeLABA- Long-acting b2-agonistBACKGROUND: Inhaled corticosteroids (ICSs) are the
mainstay of asthma treatment, but response to medication is
variable. Patients with allergic inﬂammation generally show a
better short-term response to ICSs; however, studies on pre-
dictors of long-term response are few.
OBJECTIVE: To assess whether allergic sensitization can modify
the association between ICS use and lung function decline over
20 years in adult asthma.
METHODS: We used data from the 3 clinical examinations of
the European Community Respiratory Health Survey. We
measured ICS use (no use, and use for <1.3, 1.3-8, and >8 years)
and FEV1 decline among subjects with asthma over the 2 periods
between consecutive examinations. We conducted a cohort study
combining data of the 2 periods (906 observations from 745
subjects) to assess whether the association between ICS use and
FEV1 decline was modiﬁed by allergic sensitization (IgE > 0.35
kU/L for any of house-dust mite, timothy grass, cat, or
Cladosporium).
RESULTS: FEV1 decline was similar for non-ICS users, as well as
ICS users for less than 1.3 years, with and without allergic
sensitization. However, among subjects on ICSs for a longer
period, sensitization was associated with an attenuated decline
(Pinteraction [ .006): in the group treated for more than 8 years,
FEV1 decline was on average 27 mL/y (95% CIBonferroni-adjusted,
11-42) lower for subjects with sensitization compared with
nonsensitized subjects.
CONCLUSIONS: Our study suggests that biomarkers of atopy
can predict a more favorable long-term response to ICSs. Ran-
domized controlled studies are needed to conﬁrm these
ﬁndings.  2019 The Authors. Published by Elsevier Inc. on
behalf of the American Academy of Allergy, Asthma & Immu-
nology. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(J Allergy Clin Immunol Pract 2020;8:980-8)
Key words: Allergic sensitization; Asthma; Atopy; Cohort study;
Epidemiology; IgE; Inhaled corticosteroids; Lung function
decline; Precision medicine; Response to corticosteroids
INTRODUCTION
Inhaled corticosteroids (ICSs) are the mainstay of asthma
treatment. Daily ICS use is recommended for persistent asthma,
although 2 of 3 patients with persistent asthma do not take ICSs
on a regular basis.1
ICSs can reduce airway inﬂammation, respiratory symptoms,
exacerbations, and mortality in patients with asthma.2-6 Estab-
lished evidence from clinical trials shows that ICSs can improve
lung function in the short-term.4,5 A number of cohort studies
on subjects with asthma have also shown that ICSs can attenuate
the decline in lung function over periods of 10 to 20 years.7-11Some of these studies suggested a clinical beneﬁt from early
initiation and regular use,10 and others documented exposure-
response associations for a higher dose7 or a longer period of
treatment.9
Clinical response to ICSs is variable, and identifying bio-
markers of response can improve therapeutic decisions.12,13 In a
previous analysis of data from the ﬁrst 2 waves of the European
Community Respiratory Health Survey (ECRHS I and II), we
showed that an increased duration of ICS therapy was associated
with an attenuated 10-year decline in lung function only among
subjects with a high level of total serum IgE at baseline.9 Par-
ticipants in the ECRHS have now been followed for a further 10
years.
In the present study, we used the data collected from this third
study wave (ECRHS III) to investigate whether, among subjects
with asthma, sensitization to airborne allergens modiﬁes the as-
sociation between treatment with ICSs and lung function decline
over 20 years. Secondarily, we aimed to replicate the previous
analysis in a larger sample and over the extended follow-up
period.
METHODS
Population and study design
ECRHS is an international cohort study on subjects from the
general population aged 20 to 44 years at enrollment in the period
1991 to 1993.14 At ECRHS I, a 20% random sample of participants
in a postal screening (stage 1) was invited to take part in a clinical
assessment (stage 2). In addition, a “symptomatic sample” consisting
of those who reported respiratory symptoms, asthma attacks, or use
of asthma medication in stage 1 was also invited. Participants were
followed up in the periods 1999 to 2002 (ECRHS II)15 and 2010 to
2013 (ECRHS III).16 Ethical approval was obtained for each center
from the appropriate ethics committees. Written informed consent
was obtained from participants.
Current asthma was deﬁned as having reported physician-
diagnosed asthma and at least 1 of the following: asthma-like
symptoms (wheeze, nocturnal chest tightness, attacks of breathless-
ness after activity/at rest/at nighttime), asthma attacks, use of
inhaled/oral medicines for breathing problems in the last 12 months,
or current use of inhalers, aerosols, or tablets for asthma.
The present cohort study covers an overall period of about 20
years between ECRHS I and III. To maximize the use of available
information, we estimated the duration of ICS use and lung function
decline among subjects with current asthma for the 2 follow-up
periods between ECRHS I and II (“ﬁrst period”) and between
ECRHS II and III (“second period”). Throughout the article, we use
the terms “baseline” and “end” to indicate the beginning point and
the ending point of a period, respectively. Participants with current
asthma at ECRHS I were eligible for inclusion in both periods.
Participants with current asthma at ECRHS II but not at ECRHS I
were eligible for the second period only. See a ﬂowchart of eligible
participants in Appendix E1 in this article’s Online Repository at
www.jaci-inpractice.org.
Clinical measurements
Subjects were advised to avoid using a b2-agonist or anticholinergic
inhaler for 4 hours or oral medication (b2-agonist, theophylline, or
antimuscarinic) for 8 hours before the clinical tests. Time since the
most recent use of a long-acting b2-agonist (LABA) was recorded, and
spirometric measurements from subjects who had used LABAs within
the previous 12 hours were excluded. FEV1 and forced vital capacity
J ALLERGY CLIN IMMUNOL PRACT
MARCH 2020
982 MARCON ETAL(FVC) repeatable to 150mLwere measured from at least 2 technically
satisfactory maneuvers, according to the American Thoracic Society
recommendations.17 Biomedin (Biomedin, Padova, Italy) or Sen-
sorMedics (SensorMedics, Yorba Linda, Calif) spirometers were used
in most centers at ECRHS I and II, whereas NDD EasyOne (ndd
Medical Technologies, Zurich, Switzerland) was used in all centers at
ECRHS III except for Verona and Torino.18 A set of lung function
measurements corrected for change in spirometer was also derived
according to Bridevaux et al19 and used for a sensitivity analysis.
Height and weight were measured and body mass index (BMI) was
calculated (kg/m2). At ECRHS I and II, serum levels of total IgE and
speciﬁc IgE to house-dust mite (HDM), timothy grass, cat, or Cla-
dosporium were measured using the Pharmacia CAP system (Phar-
macia, Uppsala, Sweden).16 Concentrations of total IgE above 100
kU/L were considered to be high.9 Sensitization to an allergen was
considered present when speciﬁc IgE levels were above 0.35 kU/L, the
detection limit of the assay. We considered allergic sensitization,
deﬁned as sensitization to at least 1 among the 4 allergens, as effect
modiﬁer in the main analysis.
Questionnaire data
At each time point, detailed information on asthma status, life-
style, and risk factors was collected through personal interviews, and
prebronchodilator spirometry was performed. The participants were
asked the type of inhaled/oral medication for breathing problems
they used in the last 12 months. In ECRHS II and III, participants
were asked whether they had ever used ICSs, and they could point at
the medication used in a list shown by trained interviewers. Among
users, we estimated the duration of ICS therapy during each period
on the basis of number of years of use (“used every year since the last
survey?”; if not, “how many of the years since the last survey?”) and
the average number of months of use per year. Finally, participants
were grouped into nonusers and users for less than 1.3 years, 1.3 to 8
years, and more than 8 years, on the basis of tertiles of therapy
duration calculated over both periods. We used information avail-
able at each time point about adherence to “medication prescribed
for breathing problems” to construct a proxy indicator of adherence
to ICSs. Subjects were considered to be adherent during a follow-up
period if they reported to normally take all/most of prescribed
medicines both at baseline and at end of the period.
Statistical analysis
We described the characteristics of subjects with current asthma
separately for the 2 periods. Then, we pooled the data from the 2
periods and conducted a combined analysis. The main outcome was
decline in FEV1 in milliliter per year during a period [(FEV1baseline 
FEV1end)/time, with positive values representing decline], which we
analyzed using 3-level random-intercept linear regression models,
with observations (level 1) nested into subjects (level 2) to account
for repeated measures, and subjects nested into centers (level 3). We
tested whether clustering by center signiﬁcantly improved model
ﬁtting using likelihood ratio tests. The models included the
following level 1 variables (1 observation per period): indicator of
period (ﬁrst/second); age, height, BMI, BMI2 and allergic sensiti-
zation at baseline; duration of ICS therapy; annual change in BMI
(DBMI),20 and smoking status. The latter was coded as nonsmoker
(never/past smoker at baseline and follow-up), transient smoker
(current smoker either at baseline or end of a period), or current
smoker (current smoker at both time points). The continuous var-
iables were centered at the mean calculated over both periods. An
interaction term between duration of ICS therapy and allergicsensitization was included a priori.9 The models also included sex,
education level (low if completed before age 16 years) as a proxy of
socioeconomic status, and age at asthma onset (<18 vs 18 years) as
level 2 variables (1 observation per subject). Missing data on
adjustment variables were deleted listwise.
We replicated the main analysis:
1. adjusting for a multiple propensity score, obtained using multi-
nomial logistic regression, and appropriate interaction terms (see
Appendix E2 in this article’s Online Repository at www.jaci-
inpractice.org)21;
2. modeling duration of ICS therapy as a quantitative variable, using
a method to estimate the exposure-response function for a
continuous exposure with a large proportion of unexposed sub-
jects (see Appendix E3 in this article’s Online Repository at www.
jaci-inpractice.org)22;
3. further adjusting for use of oral corticosteroids or asthma attacks
in the previous 12 months (asthma severity) at baseline; use of
LABAs (use in the previous 12 months reported: never, at
baseline of a period, at end of a period, at both time points);
occupational exposure to vapors, gas, dust, or fumes during a
period (in months), which was reconstructed on the basis of
participants’ previous and present occupations, and weighted for
intensity of exposure as explained elsewhere23;
4. restricting the analysis to subjects adherent to prescribed
medication;
5. using total serum IgE (high/low) and sensitization to each
allergen at baseline (instead of allergic sensitization) as indicators
of atopy in separate models; and
6. analyzing alternative outcomes:
 decline in FEV1/FVC (%/y) ¼ 100  (FEV1/FVCbaseline 
FEV1/FVCend)/time;
 decline in FVC (mL/y) ¼ (FVCbaseline  FVCend)/time;
 decline in FEV1 % of baseline value (%/y) ¼ 100 
[(FEV1baseline  FEV1end)/FEV1baseline]/time;
 decline in FEV1 (mL/y) calculated using measurements cor-
rected for change in spirometer.19
Adjusted mean decline in lung function was calculated by setting
quantitative and indicator variables equal to the mean and propor-
tion, respectively (calculated over the set of subjects in each analysis).
The statistical analyses were performed using STATA software,
release 15.1 (StataCorp, College Station, Texas).RESULTS
There were 17,943, 10,781, and 6841 participants in ECRHS
I, II, and III, respectively, from 28 centers; about 85% were from
the random sample (see Table E1 in this article’s Online Re-
pository at www.jaci-inpractice.org). The numbers of subjects
with current asthma eligible to be included in the ﬁrst and sec-
ond periods were 1189 and 1131, respectively (see Figure E1 in
this article’s Online Repository at www.jaci-inpractice.org). After
excluding subjects due to loss to follow-up or missing data, 522
and 384 subjects contributed data to the ﬁrst and second period,
respectively, totaling 906 observations from 745 subjects (161
participants contributed data to both periods) (Figure 1). The
distribution of subjects by center is presented in Table E2 in this
article’s Online Repository at www.jaci-inpractice.org.
The subjects included were slightly older and less likely to
smoke or use ICSs at baseline compared with those excluded
(Table I).
Included
(n=522)
Eligible for
1st period
(n=1189)
Lost to follow-up
(n=425)
Missing data 
on ICSs 
(n=80)
64% followed up 
(n=764)
Missing data on 
lung function
(n=162)
Included
(n=384)
Eligible for
2nd period
(n=1131)
Lost to follow-up
(n=473)
58% followed up 
(n=658)
Missing data 
on ICSs 
(n=173)
Missing data on 
lung function
(n=101)
Combined analysis
(n=906)*
FIGURE 1. Flowchart of the study. *From 745 participants (161 participants contributed data to both periods).
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years) for the ﬁrst period and 11.6 years (range, 8.6-15.3 years)
for the second. ICS users were 246 (47%) during the ﬁrst period
and 231 (60%) during the second period. Median duration of
therapy among users was 2.7 years (interquartile range [IQR],
0.7-8.2 years) and 4.9 years (IQR, 1.0-10.8 years), respectively.
Because of the inclusion of subjects with new-onset asthma at
ECRHS II (see Appendix E1 in this article’s Online Repository
at www.jaci-inpractice.org), age at asthma onset was higher in the
second period (mean, 20.1  13.6 years) compared with the ﬁrst
(mean, 17.1  12.5 years) (Table II). For all the allergens, the
frequency of sensitization was lower in the second period
compared with the ﬁrst. In both periods, ICS use was more
common in women and in those who were older when their
asthma began, had a family history of asthma, and had a higher
total serum IgE level (Table II). ICS users were more likely to be
sensitized and less likely to be a current smoker at baseline.
Increased duration of ICS therapy was strongly associated with
several dimensions of severity at baseline, including a lower lungfunction and more frequent use of rescue and controller medi-
cation (Table III). Within each treatment group, subjects with
sensitization had lower lung function and they were more likely
to have symptoms or use short-acting b2-agonists at baseline,
compared with nonsensitized subjects (Table III).
Median unadjusted decline in FEV1 was 30 mL/y (IQR, 10-52
mL/y) during the ﬁrst period and 37 mL/y (IQR, 24-55 mL/y)
during the second. Considering the 2 periods together (906 ob-
servations from 745 participants), decline in FEV1 was 33 mL/y
(IQR, 16-51 mL/y) and 36 mL/y (IQR,18-56 mL/y) for subjects
with and without allergic sensitization, respectively. Among
sensitized subjects, unadjusted decline in FEV1 was lower for
individuals who had used ICSs for a longer time (Ptrend ¼ .001),
ranging in median from 35 mL/y (IQR, 19-51 mL/y) among
nonusers to 27 mL/y (IQR, 0-49 mL/y) among users for more
than 8 years. However, this association was not seen among
nonsensitized subjects (Ptrend¼ .12): median decline was 36mL/y
(IQR, 1856 mL/y) among nonusers and 37 mL/y (IQR, 21-67
mL/y) among ICS users for more than 8 years.
TABLE I. Baseline participant characteristics by inclusion status in the analyses and period*
Characteristic
First period Second period
Excluded† (n [ 667) Included (n [ 522) Excluded† (n [ 747) Included (n [ 384)
Sex: female, n (%) 378 (56.7) 283 (54.2) 444 (59.4) 225 (58.6)
Low education, n (%) 85 (14.1) 70 (13.4) 97 (13.0) 51 (13.3)
Smoking habits, n (%)
Nonsmoker 283 (42.6) 242 (46.4)z 352 (47.4) 167 (43.7)
Ex-smoker 133 (20.0) 123 (23.6) 205 (27.6) 122 (31.9)
Current smoker 248 (37.4) 157 (30.1) 185 (24.9) 93 (24.4)
Age (y), mean  SD 34.9  6.1 35.6  6.2z 41.9  7.3 42.5  6.9
BMI (kg/m2), mean  SD 24.6  4.7 24.2  4.2 26.1  5.3 26.3  5.0
FEV1 (L), mean  SD 3.3  0.9 3.4  0.8z 3.2  0.8 3.2  0.8
%FEV1/FVC, mean  SD 77.7  10.0 77.3  9.7 76.7  9.2 77.3  8.2
Use of ICSs in the previous 12 mo, n (%) 217 (35.0) 99 (21.2)x 409 (55.5) 161 (42.4)x
Allergic sensitization, n (%) 377 (66.3) 306 (65.4) 449 (64.3) 225 (61.8)
*Statistics calculated on subjects with complete data; baseline refers to the start of the period.
†Subjects who were lost to follow-up or did not have complete data on lung function or ICS use.
zP < .05, for comparison of excluded vs included; obtained using Pearson c2 test (categorical variables) and Student t test (quantitative variables).
xP < .001 for comparison of excluded vs included; obtained using Pearson c2 test (categorical variables) and Student t test (quantitative variables).
TABLE II. Baseline characteristics of ICS users and nonusers, by period*
Characteristic
First period Second period
Overall
(N [ 522)
Non-ICS users
(n [ 276)
ICS users
(n [ 246) Overall (N [ 384)
Non-ICS users
(n [ 153)
ICS users
(n [ 231)
Sex: female, n (%) 283 (54.2) 129 (46.7) 154 (62.6)† 225 (58.6) 78 (51.0) 147 (63.6)z
Low education, n (%) 70 (13.4) 34 (12.4) 36 (14.6) 51 (13.3) 16 (10.5) 35 (15.2)
Current smoking, n (%) 157 (30.1) 101 (36.6) 56 (22.8)x 93 (24.4) 42 (27.5) 51 (22.1)
Age (y), mean  SD 35.6  6.2 35.5  6.1 35.7  6.3 42.5  6.9 42.1  6.8 42.7  7.0
BMI (kg/m2), mean  SD 24.2  4.2 23.9  3.8 24.5  4.7 26.3  5.0 25.5  4.3 26.7  5.4z
Age at asthma onset
(y), mean  SD
17.1  12.5 15.7  12.2 18.6  12.5x 20.1  13.6 17.9  13.1 21.6  13.8z
Family asthma, n (%) 124 (25.6) 51 (19.9) 73 (32.0)x 102 (28.2) 37 (26.4) 65 (29.3)
Total IgE, geometric
mean  SD
78.7  4.8 71.4  4.5 87.8  5.1 73.6  4.2 56.5  4.8 86.6  3.8x
Cat sensitization, n (%) 164 (35.0) 70 (28.3) 94 (42.5)† 119 (32.6) 36 (25.9) 83 (36.7)z
Cladosporium
sensitization, n (%)
58 (12.4) 22 (8.9) 36 (16.3)z 12 (3.3) 4 (2.9) 8 (3.5)
Grass pollen sensitization,
n (%)
196 (41.9) 98 (39.7) 98 (44.3) 131 (36.0) 48 (34.8) 83 (36.7)
HDM sensitization, n (%) 179 (38.3) 90 (36.4) 89 (40.3) 115 (31.5) 49 (35.3) 66 (29.2)
*Statistics calculated on subjects with complete data; baseline refers to the start of the period.
†P < .001 for comparison of non-ICS users vs ICS users; obtained using Pearson c2 test (categorical variables) and Student t test (quantitative variables).
zP < .05 for comparison of non-ICS users vs ICS users; obtained using Pearson c2 test (categorical variables) and Student t test (quantitative variables).
xP < .01 for comparison of non-ICS users vs ICS users; obtained using Pearson c2 test (categorical variables) and Student t test (quantitative variables).
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all the adjusted analyses, although centers explained only a
small percentage of total variability. As an example for the main
analysis (Figure 2, A), the proportion of variability in FEV1
decline explained by centers was 2.1%, that is, variance parti-
tioning coefﬁcient ¼ 0.021 (P ¼ .016). Decline in FEV1 was
similar for non-ICS users, as well as for users for less than 1.3
years, with and without allergic sensitization at baseline
(Figure 2, A). However, for subjects under a longer therapy,
decline in FEV1 differed according to sensitization (Pinteraction ¼
.006). In the group treated for more than 8 years, sensitized
patients had an attenuated decline in FEV1 compared withnonsensitized patients, with an average difference between the 2
groups of 27 mL/y (95% CIBonferroni, 11-42). Results were
consistent when the main analysis was repeated using a multiple
propensity score method (Figure 2, B) or when considering
duration of therapy as a quantitative variable (Figure 2, C).
Results were also consistent when adjusting for indicators of
baseline severity (see Figure E3, A and B, in this article’s
Online Repository at www.jaci-inpractice.org), concomitant
use of LABAs (Figure E3, C), or occupational exposures
(Figure E3, D).
Sensitized and nonsensitized subjects adherent to prescribed
medication were 53.6% and 45.7%, respectively (P ¼ .04).
TABLE III. Asthma severity and pharmacological treatment at baseline according to duration of ICS therapy, by allergic sensitization*
Characteristic
Without allergic sensitization (n [ 301) With allergic sensitization (n [ 531)
Non-ICS
users
Used for
<1.3 y
Used for
1.3-8 y
Used
for >8 y
Non-ICS
users
Used for
<1.3 y
Used for
1.3-8 y
Used
for >8 y
No. of subjects 141 51 52 57 244 100 93 94
FEV1 % predicted,
mean  SD
97.7  12.2 94.1  13.4 90.4  16.5 89.0  16.1† 95.2  11.8 92.1  14.3 88.0  18.2 84.5  16.5†
%FEV1/FVC, mean  SD 80.4  7.2 77.5  8.2 78.1  8.3 75.8  10.2z 78.3  8.0 76.0  8.7 76.1  9.5 71.8  10.3†
Wheezex, n (%) 82 (58.2) 41 (80.4) 35 (67.3) 46 (80.7)z 182 (74.6) 81 (81.0) 80 (86.0) 79 (84.0)
Asthma attackx, n (%) 51 (36.2) 28 (57.1) 34 (65.4) 34 (59.6)† 110 (45.1) 60 (60.6) 66 (71.0) 60 (64.5)†
Use of oral
corticosteroidsx, n (%)
3 (2.2) 2 (4.1) 6 (11.8) 10 (18.2)z 6 (2.6) 4 (4.4) 5 (5.9) 12 (13.3)z
Use of short-acting
b2-agonistsx, n (%)
34 (24.5) 28 (54.9) 29 (55.8) 44 (81.5)† 121 (50.0) 66 (68.0) 72 (83.7) 81 (89.0)†
Use of LABAsx,k, n (%) 6 (4.4) 6 (11.8) 7 (13.7) 21 (40.4)† 10 (4.2) 11 (11.6) 13 (14.8) 33 (37.9)†
Use of leukotriene receptor
antagonistsx,k, n (%)
0 (0.0) 0 (0.0) 2 (3.8) 4 (7.1)z 0 (0.0) 1 (1.0) 1 (1.1) 2 (2.2)
Vaccinated for allergyx, n (%) 3 (2.1) 1 (2.0) 2 (3.8) 0 (0.0) 10 (4.1) 6 (6.1) 4 (4.4) 0 (0.0)
*Statistics calculated on subjects with complete data (n ¼ 74 had missing data on sensitization); baseline refers to the start of the period.
†P < .001 for the overall comparison across groups; obtained using Pearson c2 or Fisher exact test (categorical variables) and ANOVA (quantitative variables).
zP < .01 for the overall comparison across groups; obtained using Pearson’s c2 or Fisher exact test (categorical variables) and ANOVA (quantitative variables).
xIn the previous 12 mo.
kNot in commerce at ECRHS I.
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medication, the results were fully consistent (Figure 3).
A similar pattern of associations was seen when considering
modiﬁcation by total serum IgE (although less evident:
Pinteraction ¼ .063; see Figure E4 in this article’s Online Re-
pository at www.jaci-inpractice.org), as well as modiﬁcation by
sensitization to each allergen separately (Figure 4). An exception
was Cladosporium, likely due to having only 11 sensitized sub-
jects who had taken ICSs for less than 1.3 years. Figure E5 in this
article’s Online Repository at www.jaci-inpractice.org illustrates
how decline in FEV1 was consistently attenuated for atopic
versus nonatopic subjects treated with ICSs for more than 8
years, regardless of the indicator of atopy used to differentiate
between the 2 groups.
When analyses were run with decline in FEV1/FVC or decline
in FVC as outcomes (see Figure E6, A and B, in this article’s
Online Repository at www.jaci-inpractice.org), the ﬁndings were
broadly consistent but the interactions were not statistically
signiﬁcant.DISCUSSION
In this large cohort study of adults with doctor-diagnosed
current asthma followed over 2 decades, we found that, among
those treated with ICSs for a longer period (>8 years), decline in
FEV1 was attenuated for subjects sensitized to any of 4 common
aeroallergens (HDM, timothy grass, cat, and Cladosporium)
compared with nonsensitized subjects. However, decline did not
differ according to sensitization among subjects treated for a
shorter period or non-ICS users. Consistent results were obtained
when considering alternative indicators of atopy.
We used observational data obtained from representative
samples of the general population in an international setting (28
centers in 13 countries). To better account for changes in ICS
use between the 2 decades, the study was designed to cover 2
consecutive periods of about 10 years, rather than a single timeinterval, and the data from the 2 periods were analyzed jointly.
This also maximized statistical power: for comparison, subjects
with complete data over 20 years were only 161.
A major challenge in observational studies on drug effective-
ness is that patients under medication generally have a more
severe form of disease than untreated patients. This “con-
founding by indication” makes it difﬁcult to disentangle the
effects of treatment from the consequences of the disease. In our
study, a longer period of ICS use was indeed associated with
more severe asthma, as well as a lower lung function at baseline,
which could also raise concerns regarding potential bias due to
regression toward the mean. However, we highlight that com-
parisons between subjects with and without sensitization within
each category of ICS use would only be marginally affected by
these potential sources of bias. The results were fully consistent
when using the propensity score method, which addresses
directly indication for drug use by assessing comparability of
subjects across treatment groups (see Figure E2 in this article’s
Online Repository at www.jaci-inpractice.org).21
Among sensitized subjects, the decline in FEV1 was lower for
long-term ICS users (1.3-8 and >8 years), compared with
nonusers and short-term users (Figure 2, A), despite the greater
baseline severity of sustained users (Table III). This suggests that
a sustained ICS use is able to mitigate the lung function effects of
severe allergy-driven inﬂammation.24,25 Asthma with allergic
sensitization is associated with type 2 airway inﬂammation and
eosinophilic endotypes.26 ICSs are particularly effective in
eosinophilic asthma,12 because eosinophils are sensitive to the
inhibitory effect of corticosteroids.27-29
Among nonsensitized subjects, in the main analysis, we
observed increased lung function decline for those using ICSs for
more than 8 years compared with nonusers or shorter time users
(Figure 2, A), which could be due to the greater impact of
chronic inﬂammation and airway remodeling in more severe
asthma. Nonsensitized subjects are likely to include patients with
noneosinophilic inﬂammation, which is less responsive to ICSs.
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A
10
20
30
40
50
60
70
80
FE
V 1
 d
ec
lin
e 
(m
L/
y)
No use <1.3 y 1.3-8 y >8 y
ICS use
p interaction= 0.009 **
B
10
20
30
40
50
60
70
80
FE
V 1
 d
ec
lin
e 
(m
L/
y)
No use <1.3 y 1.3-8 y >8 y
ICS use
p interaction= 0.003
C
10
20
30
40
50
60
70
80
FE
V 1
 d
ec
lin
e 
(m
L/
y)
0 1 2 3 4 5 6 7 8 9 10 11
Duration of ICS therapy (years)
FIGURE 2. Adjusted mean decline in FEV1 with 95% CIs by
duration of ICS therapy during follow-up, for subjects with (solid
symbols) and without (hollow symbols) allergic sensitization at
baseline (A); sensitivity analyses using a multiple propensity score
method (B) and considering therapy duration as a quantitative
variable (C). Pinteraction is the overall P value for interaction be-
tween ICS use and sensitization obtained by Wald test; complete-
case analysis: N ¼ 812, 818, and 812, respectively. Panel B:
adjusted for multiple propensity score and appropriate interaction
terms, annual change in BMI, and current smoking status. Panel C:
main independent variables were therapy duration (months), its
interaction with sensitization, and therapy duration squared
(months2). **P <.01, ***P <.001 for the comparison of subjects
with vs without sensitization (Bonferroni adjustment for multiple
testing).
p interaction= 0.034 ***
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FIGURE 3. Adjusted mean decline in FEV1 with 95% CIs by
duration of ICS therapy during follow-up, for subjects with (solid
symbols) and without (hollow symbols) allergic sensitization at
baseline: analysis restricted to subjects adherent to prescribed
medication for breathing problems. Pinteraction is the overall P value
for interaction between ICS use and sensitization obtained by
Wald test; complete-case analysis: N ¼ 379. ***P < .001 for the
comparison of subjects with vs without sensitization (Bonferroni
adjustment for multiple testing).
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effect of ICSs, because ICSs have favorable effects on several
other outcomes. Because of the observational nature of the study
and the lack of randomization, our reasoning remains
speculative.
We found a higher adherence to prescribed medication among
subjects with allergic sensitization, which could be explained by a
greater perceived beneﬁt of treatment compared with their
nonsensitized peers. Nonetheless, consistent results in the anal-
ysis restricted to adherent subjects rules out the hypothesis that
differential adherence is a major explanation of our ﬁndings.Our results were similar whatever marker of atopy was
considered as an effect modiﬁer, although in some cases the in-
teractions were less evident. The most consistent ﬁnding was an
attenuated decline in FEV1 for atopic (vs nonatopic) subjects
using ICSs for more than 8 years (Figure E5). The strongest
interaction was observed for HDM sensitization (Pinteraction <
.001), whereas nonsigniﬁcant interactions were observed for cat
and grass pollen sensitization (Pinteraction > .20). Because the
frequency of sensitization was similar for these 3 allergens in our
sample (30%-40% regardless of the period), we believe that the
stronger interaction seen for HDM is not related to statistical
power. Recent research suggests that asthma related to HDM
allergy could be particularly responsive to medication targeting
IgEs or eosinophils.30,31
The associations observed for FEV1/FVC ratio and FVC were
consistent with what we found for FEV1, except that the dif-
ferences between sensitized and nonsensitized subjects were
blunted (and the interactions were not signiﬁcant). This could be
linked to a greater response to ICSs for FEV1 compared with
FVC.
Because data on maximum attained lung function were not
available, we did not adjust for baseline FEV1 a priori to avoid
overadjustment. In fact, the baseline time points in our study
were ages during adult life (25-56 years) when FEV1 can already
be impaired as a consequence of previous accelerated decline. In
this scenario, adjustment for FEV1 could mask true differ-
ences.32,33 Nonetheless, the results were consistent when
analyzing FEV1 % of baseline (Figure E6, C).
Study limitations
Self-reporting of asthma and use of medication is a limitation
of the present study, although questionnaire-based deﬁnitions are
highly speciﬁc and widely used in epidemiology.34 To our
knowledge, validation studies of self-reported duration of ICS
A B
C D
FIGURE 4. Adjusted mean decline in FEV1 with 95% CIs by duration of ICS therapy during follow-up, for subjects with (solid symbols)
and without (hollow symbols) sensitization to HDM, timothy grass, cat, or Cladosporium allergens at baseline (A-D, respectively).
Pinteraction is the overall P value for interaction between ICS use and allergen-specific sensitization obtained by Wald test. Complete-
case analysis: N ¼ 812. *P < .05; **P < .01; ***P < .001 for the comparison of subjects with vs without sensitization (Bonfer-
roni adjustment for multiple testing).
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Aimed at improving the validity of self-reported information, we
included a conﬁrmation by a physician in the deﬁnition of
asthma, as well as a report of current respiratory symptoms or use
of medication. One further shortcoming is that we had no data
to quantify the use of medication other than ICSs, which made it
difﬁcult to disentangle response to ICSs from response to other
treatments. Nonetheless, very few subjects reported use of
leukotriene receptor antagonists or vaccination for allergy
(Table III), and the analysis adjusted for use of LABAs was
consistent. As in other epidemiological studies spanning across
decades, spirometers were changed in many centers for logistic
reasons. We are aware that performance can change when using
different instruments. However, the sensitivity analysis on FEV1
corrected for change in spirometer was completely consistent
with the main analysis (Figure E6, D). We also acknowledge as a
limitation the lack of measures of decline based on post-
bronchodilator lung function. Because of nonparticipation and
missing data, we had to exclude a number of subjects from the
analyses. However, the baseline distributions of the main vari-
ables under study (FEV1 and sensitization) were similar between
included and excluded subjects. The latter were more likely toreport a history of ICS use compared with those included, but
this is because some ICS users failed to provide additional in-
formation on duration of therapy. Finally, we did not have
baseline data on other biomarkers that could be a promising
guide for asthma treatment, such as blood or sputum eosinophils
or exhaled nitric oxide.35-37CONCLUSIONS
Our study adds further evidence to the lung function beneﬁt
of ICSs for patients with asthma, and suggests that indicators of
atopy could be useful to predict the long-term response to sus-
tained ICS treatment. Allergy tests could provide useful bio-
markers for clinical decisions regarding asthma therapy and
contribute to the advocated “precision medicine” approach in the
treatment of chronic airway diseases.35 Analyses from random-
ized controlled studies are needed to clarify this.
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Baseline variable
Before correction
(P value)
After correction
(P value)
Period <.001 .98
Sex .001 .98
Education .42 .94
Age (y) <.001 .99
Height (m) .02 .99
BMI (kg/m2) <.001 .98
Smoking status .001 .99
Allergic sensitization .91 .99
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APPENDIX E1. FLOWCHART OF ELIGIBLE
PARTICIPANTS
Participants with current asthma at ECRHS I were eligible for
inclusion in both follow-up periods, except for subjects younger
than 25 years who were excluded from the ﬁrst period (because
maximum lung growth is usually reached around that age).
Participants with current asthma at ECRHS II but not at
ECRHS I were eligible for the second period only. Subjects were
eligible for the ﬁrst period if they had current asthma at ECRHS
I, were 25 years or older, and had lung function data at ECRHS I
(n ¼ 1189) (Figure E1, A). Subjects were eligible for the second
period (Figure E1, B) (n ¼ 1131)
 if they had current asthma at ECRHS I, took part in ECRHS
II, and had lung function data at ECRHS II (n ¼ 779);
 if they had “new” current asthma at ECRHS II (ie, current
asthma at ECRHS II but not at ECRHS I) and had lung
function data at ECRHS II (n ¼ 352). This group was made
up of
B 285 subjects who had not reported “ever asthma” at
ECRHS I; that is, they had new-onset asthma at ECRHS II:
median age at diagnosis among 267 subjects with available
information was 31 years (IQR, 20-40 years);
B 67 subjects who had reported “ever asthma” at ECRHS I
but did not fulﬁll the criteria for current asthma at ECRHS
I because they lacked a physician diagnosis (n ¼ 36) or
did not report current symptoms/use of medication (n ¼
31): median age at diagnosis was 14 years (IQR, 5-23
years).
APPENDIX E2. SENSITIVITY ANALYSIS USING A
MULTIPLE PROPENSITY SCORE METHOD TO
ADJUST FOR POTENTIAL CONFOUNDERS
Propensity score (PS) methods are a set of techniques that can
be used to balance a set of covariates across treatment groups in
observational studies, aimed to simulate the balance generated by
treatment randomization.E1,E2 Multiple PS methods are an
extension of the method to 3 or more treatment groups.E1,E3
Separate PS models for each paired treatment comparison are
created using a multinomial logistic regression model.
As suggested by others,E2-E4 we tested for inclusion in the
multiple PS only baseline covariates associated with the outcome
(FEV1 decline), and we included only those covariates that were
signiﬁcantly associated in univariate analyses (P < .10). In the
following list of baseline variables tested, the variables selected are
marked with an asterisk:
 period (ﬁrst/second)*
 sex*
 education level (low/high)*
 age (years)*
 height (m)*
 BMI (kg/m2)* and BMI2 (kg2/m4)*
 smoking status (nonsmoker, past smoker, current smoker)*
 allergic sensitization (yes/no)*
 serum total IgE (low/high)
 age at asthma onset (<18 vs 18 years)
 asthma duration (years)
 family asthma (yes/no) occupation (manual, nonmanual, other/unknown)
 type of spirometer (SensorMedics volume-displacement; Sen-
sorMedics heated-wire; Vitalograph; Jaeger Masterscope; Bio-
medin; Spirotech)
 use of short-acting b2-agonists in the last 12 months (yes/no)
 use of oral corticosteroids in the last 12 months (yes/no)
 asthma attacks in the last 12 months (yes/no)
 asthma-like symptoms in the last 12 months (yes/no)
 hospital/emergency rooms admission in the last 12 months
(yes/no)
We calculated conditional predicted probabilities of belonging
to each treatment group, that is, the PSs, using a multinomial
logistic regression model with treatment group as the outcome
and all selected variables as independent variables. We then
compared visually overlap of different PSs across the 4 treatment
groups to check that each subject had the same possibility of
being in each treatment group; that is, subjects had a comparable
indication for drug use (“positivity” assumption).E2 Figure E2
shows that the distributions of the scores were similar across
the 4 treatment groups, indicating that there were no major vi-
olations of the assumption. However, when excluding the sub-
jects with nonoverlapping PSs (about 15% of the study sample),
the results were also consistent (data not shown).
In our study with k ¼ 4 treatment groups, we devised a
multiple PS score consisting of 3 scores. In fact, for a k-level
treatment, k scores are estimated and because they sum to 1, only
k  1 scores are considered for subsequent analyses. Scores 1 and
4 were the most strongly correlated (Pearson r coefﬁcient ¼
0.78). Three of the scores (1, 2, and 3) and 2 of their interaction
terms (1  2 and 1  3) were ﬁnally used for adjustment.
Interaction 2  3 was not considered because it was strongly
correlated with scores 2 and 3 (r ¼ 0.87 and 0.84, respectively).
To check for balance across treatment groups before and after
multiple PS correction, we ﬁtted models without and with
correction for multiple PS, respectively. We used linear, logistic,
or multinomial logistic regression for quantitative, binary, and
categorical covariates, respectively, with each covariate as the
dependent variable and treatment as the independent variable.E3
We tested the null hypotheses that all 3 (k 1) regression co-
efﬁcients for treatment group are jointly 0 using Wald tests. The
table below reports P values from Wald tests on the difference in
distribution of covariates across treatment groups (computed
before and after correction for multiple PSs), showing that the
multiple PSs were quite effective in balancing out differences in
covariates across treatment groups.
We then repeated the main analysis using a 3-level model
(centers/subjects/observations) adjusted for treatment group,
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(and interaction terms), annual change in BMI, and smoking
status. The results, reported in Figure 2, B, were completely
consistent with the main analysis.APPENDIX E3. SENSITIVITY ANALYSIS
CONSIDERING DURATION OF ICS THERAPY AS A
CONTINUOUS MEASURE
For sensitivity analysis we considered duration of ICS therapy
as a continuous measure. We modeled duration of ICS therapy
using a method proposed to estimate the exposure-response
function for a continuous exposure with a “spike” at 0, that is,
a large proportion of unexposed subjects.E5
We added duration of therapy with a small constant (corre-
sponding to 1 day of therapy) to avoid missing values for non-
ICS users, as suggested by Royston et al,E5 and centered at the
mean value.
We then tested, both separately and in combination, 3 in-
dicators of ICS use, with and without their interactions with
allergic sensitization:
1. a dummy for ICS use during follow-up (yes/no);
2. duration of therapy (months);
3. duration of therapy squared (months2), which was considered
to account for possible nonlinear exposure-response
associations.
Likelihood ratio tests were used to determine whether each
parameter added signiﬁcantly improved model ﬁtting (P < .10).
We used a 3-level model (centers/subjects/observations) and
included the full set of adjustment variables.
The ﬁnal model included therapy duration, its interaction
with allergic sensitization, and therapy duration squared.
The results, which are reported in Figure 2, C, are consistent
with the main analysis.APPENDIX E4. SUPPLEMENTARY INFORMATION
ON THE ECRHS
Co-ordinating center: P. Burney, S. Chinn, C. Luczynska†, D.
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FIGURE E2. Box plots showing the overlap of the PSs across treatment groups.
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FIGURE E1. Flowcharts of subjects with current asthma who were eligible for inclusion in the first follow-up period (A) and in the second
follow-up period (B). *Melbourne (no valid lung function at ECRHS I). †Cardiff and Portland (did not take part in ECRHS III), and Basel (did
not collect data on ICS use at ECRHS III).
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FIGURE E3. Adjusted mean decline in FEV1 with 95% CIs by duration of ICS therapy, for subjects with (solid symbols) and without
(hollow symbols) allergic sensitization at baseline. Sensitivity analyses with further adjustment variables. (A) Further adjusted for use of
oral corticosteroid in the previous 12 months at baseline (N ¼ 764). (B) Further adjusted for having had asthma attacks in the previous 12
months at baseline (N ¼ 808). (C) Further adjusted for use of LABAs (4-level variable: use in the previous 12 months reported never/at
baseline/at end/both at baseline and end of a period; N ¼ 749). (D) Further adjusted for cumulative occupational exposure to vapors, gas,
dust, or fumes during a period (N ¼ 716). Baseline refers to the start of the period. Pinteraction is the overall P value for interaction between
ICS use and sensitization obtained by Wald test. *** P < .001 for the comparison of subjects with vs without sensitization (Bonferroni
adjustment for multiple testing).
FIGURE E4. Adjusted mean decline in FEV1 with 95% CIs by
duration of ICS therapy during follow-up, for subjects with high
(solid symbols) and low (hollow symbols) total serum IgE at
baseline. Pinteraction is the overall P value for interaction between
ICS use and total IgE level obtained by Wald test (N ¼ 812).
FIGURE E5. Adjusted mean difference in FEV1 decline, with 95%
CIs, between ICS users for more than 8 years with sensitization/
high total IgE at baseline and ICS users for more than 8 years with
no sensitization/low total IgE (reference). Baseline refers to the
start of the period; negative values indicate attenuated decline for
atopic subjects compared with nonatopic subjects. *P < .05; **P
< .01; ***P < .001 (Bonferroni adjustment for multiple testing).
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FIGURE E6. Adjusted mean decline in lung function with 95% CIs by duration of ICS therapy, for subjects with (solid symbols) and
without (hollow symbols) allergic sensitization at baseline. Sensitivity analyses using alternative outcomes. (A) Decline in FEV1/FVC (N ¼
742). (B) Decline in FVC (N ¼ 742). (C) Decline in FEV1 % of baseline value (N ¼ 812). (D) Decline in FEV1 calculated using mea-
surements corrected for change in spirometer (N ¼ 800). Baseline refers to the start of the period. Pinteraction is the overall P value for
interaction between ICS use and sensitization obtained by Wald test. ***P < .001 for the comparison of subjects with vs without
sensitization (Bonferroni adjustment for multiple testing).
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TABLE E1. Number of participants in the clinical examinations, by center
Country Center ECRHS I (1991-1994) ECRHS II (1999-2003) ECRHS III (2010-2014)
Belgium Antwerp City 651 333 194
Antwerp South 634 386 170
Estonia Tartu 558 328 165
Germany Erfurt 731 287 336
Hamburg 1,252 303 304
Spain Albacete 626 449 244
Barcelona 516 361 213
Galdakao 592 443 385
Huelva 403 306 156
Oviedo 524 342 185
France Bordeaux 544 165 206
Grenoble 522 423 378
Montpellier 456 202 187
Paris 651 433 360
Italy Pavia 310 192 77
Turin 355 178 82
Verona 360 219 99
Iceland Reykjavik 647 524 453
Norway Bergen 835 596 365
Sweden Gothenburg 866 628 342
Umea 708 543 297
Uppsala 823 679 422
Australia Melbourne 876 637 318
Switzerland Basel 1,002 569 538
United Kingdom Cardiff 519 332 0
Ipswich 559 373 182
Norwich 581 318 183
United States Portland 842 232 0
Random sample 15,303 (85%) 9,023 (84%) 5,904 (86%)
Total 17,943 10,781 6,841
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TABLE E2. Number of subjects with current asthma who were eligible for/included in the analyses, by follow-up period
Country Center
First period Second period
Eligible Included Eligible Included
Belgium Antwerp City 33 7 24 3
Antwerp South 21 6 19 2
Estonia Tartu 5 2 6 2
Germany Erfurt 7 3 19 8
Hamburg 36 6 23 13
Spain Albacete 37 13 44 19
Barcelona 30 12 36 11
Galdakao 23 10 43 29
Huelva 14 12 31 11
Oviedo 20 9 32 15
France Bordeaux 48 8 20 5
Grenoble 45 33 55 25
Montpellier 55 8 18 5
Paris 43 24 40 12
Italy Pavia 9 5 11 5
Turin 30 14 22 7
Verona 19 12 19 5
Iceland Reykjavik 54 37 75 39
Norway Bergen 37 24 65 19
Sweden Gothenburg 69 32 76 26
Umea 94 50 92 27
Uppsala 80 44 97 41
Australia Melbourne 0* 0 135 37
Switzerland Basel 88 38 0† 0
United Kingdom Cardiff 92 29 0z 0
Ipswich 71 37 56 10
Norwich 70 34 73 8
United States Portland 59 13 0z 0
Random sample 599 (50%) 249 (48%) 597 (53%) 201 (52%)
Total 1189 522 1131 384
*Valid lung function measurements not available.
†Data on ICS use not collected at ECRHS III.
zDid not take part in ECRHS III.
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